Scholar Rock (SRRK) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scholar Rock (SRRK) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 9.1% versus a gain of 3.5%. Over five years, TARS leads with a +153.2% price change compared with +54.7% for SRRK. Scholar Rock is the larger company by market cap ($5.14 billion vs $3.38 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRRK | TARS |
|---|---|---|
| Share price | $42.20 | $72.22 |
| Market cap | $5.14B | $3.38B |
| 1-day change | 0.00% | -1.89% |
| YTD return | -4.20% | -11.80% |
| 1-year return | +9.07% | +3.54% |
| 5-year return | +54.75% | +153.23% |
| EPS (TTM) | $-3.32 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | $-377.94M | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $61.76 | $91.53 |
| 52-week low | $27.07 | $53.89 |
| Distance from 52-week high | -31.67% | -21.10% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +66.92% | +37.77% |
| Average volume | 1.53M | 870.50K |
| Shares outstanding | 121.79M | 46.79M |
| Employees | 289 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
SRRK vs TARS FAQ
Which is bigger, Scholar Rock or Tarsus Pharmaceuticals?
Scholar Rock (SRRK) is larger, with a market capitalization of $5.14B compared with $3.38B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, SRRK or TARS?
SRRK returned +9.07% over the past 12 months, compared with +3.54% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Scholar Rock and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.